As of February 15, 2026, a new ClinicalTrials.gov entry outlines a feasibility and outcomes registry for lumenless defibrillation leads used in conduction system pacing. The sponsor is University Hospital Caen. The study targets Cardiac Resynchronization Therapy with Left Bundle Branch Area Pacing and is not yet recruiting. Clinicians and device sponsors will watch how data from this registry evolve to inform practice and regulation.
Meta description A new registry study in conduction system pacing tests lumenless defibrillation leads and regulatory implications for Cardiac Resynchronization Therapy.
What is conduction system pacing and why are lumenless defibrillation leads involved?
Conduction system pacing aims to engage the heart’s natural conduction pathways to improve synchronization. The Left Bundle Branch Area Pacing approach targets pacing near the left bundle zone as part of Cardiac Resynchronization Therapy. The registry described here centers on lumenless defibrillation leads used in this approach and will gather data on feasibility and clinical outcomes to inform safety and performance considerations.
What is the study design and current status?
The entry describes a feasibility and outcomes registry rather than a traditional randomized trial. The design will capture real world experiences with lumenless defibrillation leads in conduction system pacing as part of Cardiac Resynchronization Therapy. The sponsor is University Hospital Caen and the record notes Not yet recruiting. Data elements may include lead performance, safety signals and patient outcomes while using Left Bundle Branch Area Pacing.
Why does this matter from a regulatory perspective?
Registries are recognized as important sources of real world data that can support safety and performance assessments for medical devices. This registry will be observed for data quality and reporting standards and may influence future guidance related to lumenless defibrillation leads in conduction system pacing. The statements in the record reflect sponsor and investigator intent rather than independent conclusions. From a regulatory viewpoint this type of data flow can inform risk assessment, post market surveillance plans and design considerations for devices used in Cardiac Resynchronization Therapy.
What should clinicians and patients understand?
For clinicians the registry offers a view into how lumenless defibrillation leads perform in real world Left Bundle Branch Area Pacing. The data may help shape decision making about device selection, implantation strategies and follow up. For patients the registry signals ongoing efforts to optimize outcomes in Cardiac Resynchronization Therapy and to track safety signals across diverse practice settings. Until results emerge, changes to standard care remain guided by existing guidelines and physician judgment.
Who is sponsoring and where is this study conducted?
The sponsor is University Hospital Caen, a center with research and clinical duties in cardiac rhythm management. The public record currently provides limited detail on additional study sites or enrollment plans beyond Not yet recruiting, but the involvement of this center underscores cross border awareness of conduction system pacing approaches.
FAQ
- 1. What is being studied?
The registry evaluates a feasibility and outcomes program for lumenless defibrillation leads used in conduction system pacing for Cardiac Resynchronization Therapy. - 2. Who sponsors?
The sponsor is University Hospital Caen. - 3. What is the status?
The registry is not yet recruiting.
Conclusion
This registry represents a structured effort to collect real world information on a niche set of devices used with conduction system pacing in Cardiac Resynchronization Therapy. While no results are available yet, stakeholders should monitor the project for data that may inform practice, safety oversight and future regulatory considerations. The outcome focus will be on feasibility, safety signals and patient oriented endpoints as data accumulate.
Disclaimer
This article is intended for professionals and should not be considered legal or regulatory advice. It reflects reported information and does not constitute a binding interpretation of any regulatory decision.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07406737?term=medical+device